Yuhui Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuhui Liu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Liheng Liu
Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China
2 shared publications - Erhu Jin
Department of Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
1 shared publication Feng Liu
School of Information Engineering Shandong Youth University of Political Science Jinan China
1 shared publicationHaiyan Zeng
Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, China
1 shared publicationHaoran Chen
Department of Radiology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China
1 shared publicationHongtu Yuan
Department of Pathology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan People's Republic of China
1 shared publication
Latest Publications
- Open Access
- 21 December 2025
- Published by Wiley in Thoracic Cancer
- Vol. 16 (24) , e70208
Diagnostic Value of Photon‐Counting CT in Pericardial Metastases: A Single‐Center Retrospective Study
Pericardial metastases are common in advanced cancers but often remain undetected due to subtle symptoms. Photon‐counting CT ( PCT ) offers improved spatial resolution and contrast‐to‐noise ratio ( CNR ) compared with conventional CT ( CCT ), potentially enhancing diagnostic performance. In this retrospective single‐center study, patients diagnosed with pericardial metastases by transthoracic echocardiography (TTE) between April and September 2025, who underwent both unenhanced and contrast‐enhanced chest CT were included. After Propensity Score Matching (PSM), two groups were established: the PCT group ( n = 11; reconstructions at 0.4 and 1 mm) and the CCT group ( n = 22). Diagnostic sensitivity, image quality, and radiation dose were assessed, with TTE as the reference standard. PCT‐0.4 mm demonstrated the highest overall sensitivity (91.5%) and small‐lesion sensitivity (88.9%), followed by PCT‐1 mm (87.2% and 83.3%) and CCT‐1 mm (86.1% and 78.6%). Although not statistically significant, PCT showed consistently better lesion detection. The PCT‐0.4 mm group showed higher standardized CNR versus CCT‐1 mm (Tukey–Kramer p = 0.021) but not versus PCT‐1 mm ( p = 0.641); overall one‐way ANOVA p = 0.020, whereas SNR did not differ among groups (ANOVA p = 0.18). Radiation exposure was significantly lower with PCT than CCT (ED: 11.7 ± 3.9 vs. 20.6 ± 6.6 mSv; p < 0.001). Compared with the 1‐mm CCT reconstruction, the 0.4‐mm PCT showed a trend toward improved detection of both overall and small pericardial metastases, enhanced image quality, and reduced radiation dose, highlighting its potential clinical value in managing pericardial metastases.
- 21 December 2025
- Published by Wiley in Thoracic Cancer
- Vol. 16 (24) , e70208
Open AccessDiagnostic Value of Photon‐Counting CT in Pericardial Metastases: A Single‐Center Retrospective Study
Pericardial metastases are common in advanced cancers but often remain undetected due to subtle symptoms. Photon‐counting CT ( PCT ) offers improved spatial resolution and contrast‐to‐noise ratio ( CNR ) compared with conventional CT ( CCT ), potentially enhancing diagnostic performance. In this retrospective single‐center study, patients diagnosed with pericardial metastases by transthoracic echocardiography (TTE) between April and September 2025, who underwent both unenhanced and contrast‐enhanced chest CT were included. After Propensity Score Matching (PSM), two groups were established: the PCT group ( n = 11; reconstructions at 0.4 and 1 mm) and the CCT group ( n = 22). Diagnostic sensitivity, image quality, and radiation dose were assessed, with TTE as the reference standard. PCT‐0.4 mm demonstrated the highest overall sensitivity (91.5%) and small‐lesion sensitivity (88.9%), followed by PCT‐1 mm (87.2% and 83.3%) and CCT‐1 mm (86.1% and 78.6%). Although not statistically significant, PCT showed consistently better lesion detection. The PCT‐0.4 mm group showed higher standardized CNR versus CCT‐1 mm (Tukey–Kramer p = 0.021) but not versus PCT‐1 mm ( p = 0.641); overall one‐way ANOVA p = 0.020, whereas SNR did not differ among groups (ANOVA p = 0.18). Radiation exposure was significantly lower with PCT than CCT (ED: 11.7 ± 3.9 vs. 20.6 ± 6.6 mSv; p < 0.001). Compared with the 1‐mm CCT reconstruction, the 0.4‐mm PCT showed a trend toward improved detection of both overall and small pericardial metastases, enhanced image quality, and reduced radiation dose, highlighting its potential clinical value in managing pericardial metastases.
- Open Access
- 4 December 2022
- Published by Wiley in Thoracic Cancer
- Vol. 14 (1) , 89-90
Aspergillus ball crawling out of pulmonary bullae
Chest CT images of the patient in 2016, 2017, 2018, and 2019. The lesion was significantly larger compared with its size in 2016
- 4 December 2022
- Published by Wiley in Thoracic Cancer
- Vol. 14 (1) , 89-90
Open AccessAspergillus ball crawling out of pulmonary bullae
Chest CT images of the patient in 2016, 2017, 2018, and 2019. The lesion was significantly larger compared with its size in 2016
- Open Access
- 17 May 2018
- Published by Wiley in Thoracic Cancer
- Vol. 9 (7) , 865-873
Magnetic resonance imaging evaluation of treatment efficacy and prognosis for brain metastases in lung cancer patients after radiotherapy: A preliminary study
Background: This study used magnetic resonance imaging (MRI) to monitor changes to brain metastases and investigate the imaging signs used to evaluate treatment efficacy and determine prognosis following radiotherapy for brain metastases from lung cancer.Methods: A total of 60 non‐small cell lung cancer patients with brain oligometastases were selected. MRI scans were conducted before and 3, 6, 9, 12, 18, 24, and 30 months after radiotherapy. The tumor and peritumoral edema diameters, Cho/Cr values, elevation of the Lip peak value, and whether the island (yu‐yuan) sign or high‐signal ring were present on T2 fluid‐attenuated inversion recovery (FLAIR) imaging were recorded for each metastasis.Results: The mortality risk was higher the earlier the maximum value of peritumoral edema diameter was reached, when there were fewer island signs, and when brain metastases did not present as tumor progression on imaging. There were significant differences in the average peritumoral edema diameter, apparent diffusion coefficient value, the number of elevated Lip peak values, and the number of T2 FLAIR imaging high‐signal rings in a year after radiotherapy in 14 patients with a survival period < 1 year compared to patients with a survival period > 2 years.Conclusion: After radiotherapy for brain metastases, patients with the island sign had longer survival periods, high‐signal rings in T2 FLAIR, elevated Lip peaks, and reduced apparent diffusion coefficient values, indicating tumor necrosis. Increased diameter of metastases and Cho/Cr > 2 cannot serve as reliable indicators of brain metastasis progression.
- 17 May 2018
- Published by Wiley in Thoracic Cancer
- Vol. 9 (7) , 865-873
Open AccessMagnetic resonance imaging evaluation of treatment efficacy and prognosis for brain metastases in lung cancer patients after radiotherapy: A preliminary study
Background: This study used magnetic resonance imaging (MRI) to monitor changes to brain metastases and investigate the imaging signs used to evaluate treatment efficacy and determine prognosis following radiotherapy for brain metastases from lung cancer.Methods: A total of 60 non‐small cell lung cancer patients with brain oligometastases were selected. MRI scans were conducted before and 3, 6, 9, 12, 18, 24, and 30 months after radiotherapy. The tumor and peritumoral edema diameters, Cho/Cr values, elevation of the Lip peak value, and whether the island (yu‐yuan) sign or high‐signal ring were present on T2 fluid‐attenuated inversion recovery (FLAIR) imaging were recorded for each metastasis.Results: The mortality risk was higher the earlier the maximum value of peritumoral edema diameter was reached, when there were fewer island signs, and when brain metastases did not present as tumor progression on imaging. There were significant differences in the average peritumoral edema diameter, apparent diffusion coefficient value, the number of elevated Lip peak values, and the number of T2 FLAIR imaging high‐signal rings in a year after radiotherapy in 14 patients with a survival period < 1 year compared to patients with a survival period > 2 years.Conclusion: After radiotherapy for brain metastases, patients with the island sign had longer survival periods, high‐signal rings in T2 FLAIR, elevated Lip peaks, and reduced apparent diffusion coefficient values, indicating tumor necrosis. Increased diameter of metastases and Cho/Cr > 2 cannot serve as reliable indicators of brain metastasis progression.
- Open Access
- 18 March 2015
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 16 (5) , 1925-1928
CT Findings of Persistent Pure Ground Glass Opacity: Can We Predict the Invasiveness?
To investigate whether CT findings can predict the invasiveness of persistent cancerous pure ground glass opacity (pGGO) by correlating the CT imaging features of persistent pGGO with pathological changes. Ninety five patients with persistent pGGOs were included. Three radiologists evaluated the morphologic features of these pGGOs at high resolution CT (HRCT). Binary logistic regression was used to assess the association between CT findings and histopathological classification (pre-invasive and invasive groups). Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic performance of diameters. A total of 105 pGGOs were identified. Between pre-invasive (atypical adenomatous hyperplasia, AAH, and adenocarcinoma in situ, AIS) and invasive group (minimally invasive adenocarcinoma, MIA and invasive lung adenocarcinomas, ILA), there were significant differences in diameter, spiculation and vessel dilatation (p0.05). The optimal threshold value of the diameters to predict the invasiveness of pGGO was 12.50mm. HRCT features can predict the invasiveness of persistent pGGO. The pGGO with a diameter more than 12.50mm, presences of spiculation and vessel dilatation are important factors to differentiate invasive adenocarcinoma from pre-invasive cancerous lesions.
- 18 March 2015
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 16 (5) , 1925-1928
Open AccessCT Findings of Persistent Pure Ground Glass Opacity: Can We Predict the Invasiveness?
To investigate whether CT findings can predict the invasiveness of persistent cancerous pure ground glass opacity (pGGO) by correlating the CT imaging features of persistent pGGO with pathological changes. Ninety five patients with persistent pGGOs were included. Three radiologists evaluated the morphologic features of these pGGOs at high resolution CT (HRCT). Binary logistic regression was used to assess the association between CT findings and histopathological classification (pre-invasive and invasive groups). Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic performance of diameters. A total of 105 pGGOs were identified. Between pre-invasive (atypical adenomatous hyperplasia, AAH, and adenocarcinoma in situ, AIS) and invasive group (minimally invasive adenocarcinoma, MIA and invasive lung adenocarcinomas, ILA), there were significant differences in diameter, spiculation and vessel dilatation (p0.05). The optimal threshold value of the diameters to predict the invasiveness of pGGO was 12.50mm. HRCT features can predict the invasiveness of persistent pGGO. The pGGO with a diameter more than 12.50mm, presences of spiculation and vessel dilatation are important factors to differentiate invasive adenocarcinoma from pre-invasive cancerous lesions.